Interventional {{label}}

Motor-Point Stimulation for Conditioning the Diaphragm of Patients With ALS

Please note: All trial information reflects the latest data available from the sponsor on ClinicalTrials.gov and other public databases. However, these sources may occasionally be outdated or inaccurate. For the most current information, we recommend contacting the trial sponsor or sites directly.

Overview

{{trial.Sponsor}} {{trial.Sponsor}}
{{route.Name}}
{{route.Name}}
Approved by FDA
Approved outside USA
Is a supplement

Details

Enrollment Criteria

{{m.Name}}
{{trial.ExternalId}} (First Published: {{trial.FirstPublishedDate|date}} on {{trial.SourceName}})
The overall goal of this study is to determine whether the DPS delays the respiratory decline of patients with Amyotrophic Lateral Sclerosis (ALS) thereby increasing their lifespan by conditioning the diaphragm with laparoscopically-placed electrodes.

This device currently holds an Investigational Device Exemption No. G040142 in the United States and is currently undergoing clinical trials at University Hospitals (Cleveland), Johns Hopkins, Mayo Clinic Jacksonville, California Pacific Medical Center (CPMC), Henry Ford Health System, The Methodist Hospital, and Stanford University.

18 years and older. Both genders. Accepting healthy volunteers.

Locations
{{countryGroup}}
{{regionGroup}}
{{location.Facility}}
{{location.City !== '' ? location.City + ',' : ''}} {{location.RegionAbbreviation}} {{location.PostalCode}} {{location.Country}}
{{location.Facility !== '' ? location.Facility + ',' : ''}} {{location.City !== '' ? location.City + ',' : ''}} {{location.RegionAbbreviation}} {{location.PostalCode}} {{location.Country}}
Location Contact: {{location.Contact.Name}} {{location.Contact.Name}} Phone: {{location.Contact.Phone}}
Join the ALS Research Collaborative (ARC) Study Today!
Ready to make a difference in ALS research?
Join the ARC Study! Whether you're living with ALS or an asymptomatic gene carrier, your participation can help inform ALS research and lead to new treatments.
ALS Research Collaborative
Thank You to Our Sponsors
Mitsubishi Tanabe Pharma